Actual Medicinal Product (AMP) Darifenacin 7.5mg modified-release tablets (A A H Pharmaceuticals Ltd)

Stability Information

(Some stability information inherited from generic)

Stability
compatible_special_measures logo Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
Notes

Light sensitive medicine. Store in light resistant container. No stability data in MCAs available.

Provenance

This recommendation is based on the products Emselex 7.5mg prolonged-release tablets (pharma and GmbH) and Darifenacin 7.5mg prolonged-release tablets (Aristo Pharma Limited).

Generic
Darifenacin
Formulation
Darifenacin 7.5mg modified-release tablets
  • Darifenacin
    • Darifenacin 7.5mg modified-release tablets

      • Darifenacin 7.5mg modified-release tablets (A A H Pharmaceuticals Ltd)